| Autor: |
Majid Asawaeer, MD, Benjamin Widener, MD, Varda Singhal, MBBS, Matthew J. DeVries, MD, Debra J. Romberger, MD, Alan R. Erickson, MD, Yiannis S. Chatzizisis, MD, PhD |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
JACC: Case Reports, Vol 2, Iss 10, Pp 1553-1557 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2666-0849 |
| DOI: |
10.1016/j.jaccas.2020.06.041 |
| Popis: |
Treatment of cardiac sarcoidosis is challenging, as the disease can be refractory to traditional treatment with steroids. Infliximab, a tumor necrosis factor-α inhibitor, has been reportedly used in cardiac sarcoidosis, but published evidence is limited. The potential cardiotoxicity of infliximab and the Food and Drug Administration black-box warning for patients with heart failure have hindered the use of this agent in cardiac sarcoidosis. Here, we report a case of refractory cardiac sarcoidosis successfully treated with infliximab and discuss the important role of fluorine-18–fluorodeoxyglucose positron emission tomography in prognostication and guidance of therapy. (Level of Difficulty: Intermediate.) |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
